



**ASX ANNOUNCEMENT**

**13 March 2009**

## **Appointment of Mel Bridges as Company Director**

The Board of Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has with great pleasure announced today the appointment of Mr Mel Bridges as a Director of the company.

Mel has spent the majority of his career in the biotech and healthcare industry, where he has over 30 years experience building successful biotech companies and commercialising a wide range of Australian technology.

He was co-founder of listed companies Panbio and ImpediMed, and is currently the Chairman of ASX listed companies Alchemia, ImpediMed and Incitive as well as a Director of Benitec Ltd and Genera Biosystems Ltd. Mel is also the Chairman of a number of private biotechnology companies based in Brisbane, Sydney and Melbourne.

As Chairman, Mel was lead negotiator on the successful trade sale of Four Hats Capital backed, Catapult Genetics to Pfizer.

Mel has an exceptional track record in founding, as well as assisting, a variety of technology companies to high end exits. Mel has a 100% track record to date in completing IPO and Trade Sale exits for investors – the latest, ImpediMed, oversubscribed in a difficult market, drawing a 75% institutional register. He has been involved in more commercial and M&A transactions and liquidity events for investors than any other angel investor in Australia – to date his track record exceeds \$1 billion dollars in completed transactions and we can expect more to come.

Mel a serial entrepreneur having founded five successful technology companies. He has received numerous business and industry awards including the AusBiotech Chairman's Gold Medal and the Queensland Government Premier's award for his contribution to the biotechnology industry. Mel was also awarded the Ernst & Young Entrepreneur of the Year and the Business Bulletin Business Star Award.

During his career he has raised over \$300 million in biotech investment capital.

The Chairman of Tissue Therapies Ltd, Mr Roger Clarke said, "The directors of Tissue Therapies are delighted that Mel has agreed to join the Board. His substantial and highly successful track record in biotechnology commercialisation will be of great practical and immediate value to Tissue Therapies in the commercialisation of VitroGro®.

We look forward to working with Mel at this pivotal time in the history of the company and his involvement in the commercial negotiations for the development and sale of VitroGro® products to transform wound care, as well as other applications," Mr Clarke said.

Further information: Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: +61 (0)7 3839 9938

Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

### **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)